The FDA cleared the investigational new drug (IND) application for the use of CYNK-001 in adults with coronavirus disease 2019 (COVID-19), according to Celularity, the agent’s manufacturer.1
The company also announced that it will immediately begin a phase I/II clinical study of CYNK-001 in collaboration with Sorrento Therapeutics, which will include up to 86 patients with COVID-19.
“We are confident that our strategic relationship with Sorrento will help assure our ability to meet the scale requirements for our efforts in COVID-19,” Robert Hariri, MD, PhD, CEO for Celularity, said in a press release.
Individuals who are enrolled in the trial will receive infusions of natural killer (NK) cells, which the company believes could kill cells infected with the virus and address the resulting inflammation caused by the immune system.
Infectious Disease Research Institute (IDRI), a…
